



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

Innovasis, Incorporated
Mr. Marshall McCarty
Director QA/RA
614 East 3900 South
Salt Lake City, Utah 84107

June 19, 2015

Re: K150500

Trade/Device Name: Px™ PEEK IBF System
Regulation Number: 21 CFR 888.3080
Regulation Name: Intervertebral body fusion device
Regulatory Class: Class II
Product Code: MAX
Dated: May 19, 2015
Received: May 20, 2015

Dear Mr. McCarty:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

Mark N. Melkerson -S

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)
K150500

K150500

Page 1 of 1

Device Name
Px™ PEEK IBF System

Indications for Use (Describe)

The Innovasis Px™ PEEK IBF System is an intervertebral body fusion device for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbar spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to a Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). These implants are used to facilitate fusion in the lumbar spine and are placed via either a posterior (PLIF) or modified transforaminal (T-PLIF) approach.

This device is intended to be used in pairs and with internal supplemental spinal fixation systems such as the Innovasis Excella® Spinal System. The interior of the Px implant is intended to be packed with autograft.

Type of Use (Select one or both, as applicable)

☒ Prescription Use (Part 21 CFR 801 Subpart D)

☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

 <small>INNOVATE / INVOLVE / INVENT</small>	Px PEEK IBF	K150500
		June 16, 2015 Page 1 of 3

510(k) Summary Report:

PxTM PEEK IBF System

Company: Innovasis, Inc.
614 E. 3900 South
Salt Lake City, UT 84107

Contact: Marshall C. McCarty
Phone: (801) 261-2236
mmccarty@innovasis.com

Trade Name: PxTM PEEK IBF System

Common Name: Intervertebral body fusion device

Classification: Regulation No.: 21CFR 888.3080
Class 2

Product Code: MAX

Review Panel: Orthopedic ASDB

Applicable Standards:

- ASTM F560-13 Standard Specification for Unalloyed Tantalum for Surgical Implant Applications
- ASTM F983-86 (Reapproved 2013) Standard Practice for Permanent Marking of Orthopedic Implant Components
- ASTM F2026-12 Standard Specification for Polyetheretherketone (PEEK) Polymers for Surgical Implant Applications
- ASTM F2077-11 Test Methods for Intervertebral Body Fusion Devices
- ASTM F2267-04 (Reapproved 2011) Standard Test Method for Measuring Load Induced Subsidence of Intervertebral Body Fusion Device Under Static Axial Compression
- ISO 17665-1: 2006 (Reapproved 2013) Sterilization of Healthcare Products – Moist Heat – Part 1 Requirements for the Development, Validation and Routine Control of a Sterilization Process for Medical Devices

Primary Predicate: K073177 Pioneer Bullet Tip IBF
This predicate has not been subject to a design-related recall.

	Px PEEK IBF	K150500
		June 16, 2015 Page 2 of 3

Add'l Predicate: P960025 Jaguar IF / Brantigan Cage

Device Description: *Px™ PEEK IBF System*

The Innovasis *Px™ PEEK IBF* is designed for use in a posterior (PLIF) approach to the lumbar spine. Manufactured by Innovasis from implant grade polyetheretherketone (PEEK) conforming to ASTM F2026, the *Px* has excellent strength, stiffness and dimensional stability, with a modulus of elasticity similar to human vertebral bone. The device is radiolucent allowing straightforward assessment of the fusion process, while tantalum spheres are located around the periphery of the device to allow implant visualization during the procedure.

The single use implant devices feature an open cavity in the interior geometry to accommodate bone graft and maximize bone in-growth, as well as a convex shape with anti-migration teeth to engage the vertebral endplates and prevent expulsion. The implants are offered in a variety of different sizes to fit the anatomical needs of a wide variety of patients. Reusable instruments to support the PLIF surgery are provided with the implants in custom sterilization trays.

Performance Data: (Non-clinical)—Performance testing per ASTM F2077-11 and F2267-04 for Static Axial Compression, Dynamic Axial Compression, Subsidence and Expulsion, indicates that the *Px PEEK IBF* is capable of performing in accordance with its intended use.

Materials: The implants are machined from medical grade Solvay Zeniva ZA-500 and Evonik VESTAKEEP i4R polyetheretherketone per ASTM F2026. The radiographic markers meet ASTM F560 for unalloyed Tantalum.

Intended Use: The Innovasis *Px PEEK IBF System* is an intervertebral body fusion device intended to stabilize a spinal segment to promote fusion using bone graft, in order to restrict motion and decrease pain.

Users of these products are limited to physicians trained in orthopedic surgery. Clinical locations include hospitals and surgery sites equipped to perform spinal surgery.

Indications for Use: The Innovasis *Px™ PEEK IBF System* is an intervertebral body fusion device for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbar spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These

This device is intended to be used in pairs and with internal supplemental spinal fixation systems such as the Innovasis *Excella® Spinal System*. The interior of the *Px* implant is intended to be packed with autograft.

The *Px PEEK IBF System* has been subjected to risk analysis, engineering analysis and testing to recognized standards and has been shown to be substantially equivalent to the predicate device, K073177 Pioneer Surgical Technology Interbody Fusion *Bullet Tip IBF* and reference device P960025 Depuy Spine *Jaguar IF/Brantigan Cage*.

Á
Á
Á
Á

sió
Á

The conclusions drawn from the nonclinical tests demonstrate that the subject device is as safe and as effective, and performs as well as or better than the legally marketed predicate device.